Search

Your search keyword '"Ramji, Alnoor"' showing total 58 results

Search Constraints

Start Over You searched for: Author "Ramji, Alnoor" Remove constraint Author: "Ramji, Alnoor" Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
58 results on '"Ramji, Alnoor"'

Search Results

1. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

2. A global research priority agenda to advance public health responses to fatty liver disease

3. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

4. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

5. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

7. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

12. THU-207 - Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada

15. FRI-151 - Strategies to eliminate hepatitis C virus infection in the Americas

19. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

20. GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial

21. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts

22. A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal on adenoma detection.

23. Deep Learning Based Shear Wave Detection and Segmentation Tool for Use in Point-of-Care for Chronic Liver Disease Assessments.

24. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.

27. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.

32. Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection.

37. AS091 - A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results

38. SAT461 - Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials.

39. SAT447 - All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada.

40. THU448 - Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence.

42. AS070 - Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection.

43. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.

44. FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results.

46. SAT-238-The impact of SVR from direct acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort.

Catalog

Books, media, physical & digital resources